Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE: Psilocybin and taVNS for Emotional Well-being
NCT05866471Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2025
- Primary completion
- Nov 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of psilocybin (4 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Memory Experiences Questionnaire at 8 weeks, Functional Magnetic Resonance Imaging at Day 56 and 2 more. Started Jan 2025; status: recruiting.
02
Drugs
psilocybin
Beyond the preview
Go deeper on NCT05866471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05866471.